0 seconds of 1 minute, 22 secondsVolume 0%
Press shift question mark to access a list of keyboard shortcuts
00:00
01:22
01:22
 
  • Psyence Group (PSYG) has received ISO Certification for its ISO22000 graded Psilocybin production facility in Lesotho, Southern Africa
  • ISO 22000 is a globally accepted international standard that specifies the requirements for food safety management systems
  • Tony Budden, Psyence Chief Strategy Officer and Head of Psyence Group sat down with Dave Jackson to discuss the news
  • Psyence’s facility is licensed to cultivate and export psilocybin mushrooms for the legal medical and research markets
  • With this certification, Psyence is one step closer to producing pharmaceutical grade product for human clinical trials
  • Psyence is a public life science biotechnology company focused on natural psychedelics
  • Psysence Group Inc. (PSYG) opened trading at C$0.13 per share

Psyence Group (PSYG) has received ISO Certification through the British Standards Institute for its ISO22000 graded Psilocybin production facility in Lesotho, Southern Africa.

Tony Budden, Psyence Chief Strategy Officer and Head of Psyence Group sat down with Dave Jackson to discuss the news.

ISO 22000 is a globally accepted international standard that specifies the requirements for food safety management systems.

Psyence’s facility, which is federally licensed to cultivate and export psilocybin mushrooms for the legal medical and research markets has been operational since January 2021. The facility was designed and constructed to ISO 14644-1 cleanroom specifications and engineering design principles. This design allows various parts of the process to comply with the Good Manufacturing Practice (GMP) Standards required for product safety and quality in order to meet the certification needs of the BSI.

With this certification, Psyence is one step closer to producing pharmaceutical-grade products for human clinical trials, including Psyence’s clinical trial in the field of palliative care and clinical trials run by research organizations.

Psyence is a public life science biotechnology company with a focus on natural psychedelics. Psyence works with natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care.

Psysence Group Inc. (PSYG) opened trading at C$0.13 per share.

More From The Market Online
ai generated stock image.

@ the Bell: Did markets grow on the first day of spring?

TSX growth was driven by strong performances in the energy and financial sectors, supported by rising oil prices.
Cannabis nursery

Aurora makes breakthrough in cannabis mildew resistance

Aurora Cannabis (TSX:ACB) announces the discovery of PM2, a new source of genetic resistance for cannabis plants against powdery mildew.
Stock image generated with AI

@ the Bell: TSX rallies in the face of Fed’s interest-rate verdict

The TSX moved higher on Wednesday as investors braced for the US Federal Reserve's interest-rate verdict and contend with weak economic data.